MARKET

SNY

SNY

Sanofi FR
NASDAQ
47.15
+0.85
+1.84%
After Hours: 47.19 +0.04 +0.08% 18:45 04/22 EDT
OPEN
46.14
PREV CLOSE
46.30
HIGH
47.16
LOW
46.12
VOLUME
2.09M
TURNOVER
0
52 WEEK HIGH
57.82
52 WEEK LOW
42.63
MARKET CAP
117.71B
P/E (TTM)
19.88
1D
5D
1M
3M
1Y
5Y
Sanofi's Rilzabrutinib LUNA 3 Phase 3 Study Met Primary Endpoint In Immune Thrombocytopenia
Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia. The drug is one of 12 potential medicines and vaccines in Sanofi's robust immunology pipeline. The drug has potential to provide a clinically meaningful benefit to patients living with ITP.
Benzinga · 2h ago
Sanofi Says Blood-Disorder Drug Meets Key Target in Late-Stage Trial
Sanofi says its drug candidate met a primary goal of a late-stage clinical trial in immune thrombocytopenia, a blood disorder. The company plans regulatory submissions in the U.S. And the EU by the end of the year. Sanofi's drug candidate rilzabrutinib met the primary goal in the study.
Dow Jones · 2h ago
Sanofi: Rilzabrutinib LUNA 3 Phase 3 Study Meets Primary Endpoint In Immune Thrombocytopenia
NASDAQ · 2h ago
SANOFI - REGULATORY SUBMISSIONS IN US AND EU ANTICIPATED BY YEAR-END
Reuters · 2h ago
Health Care Sector Update for 04/22/2024: CAH, GH, SNY
NASDAQ · 14h ago
Sanofi reportedly settles 4K Zantac cases for $100M
Healthcare Sanofi reportedly settles 4K Zantac cases for $100M. Under the settlement, Sanofi will pay around $25,000 per claim. The suits alleged that Sanofi failed to adequately warn consumers about the safety of its heartburn drug. The drug was pulled off the market in 2019 over concerns it could produce a carcinogen.
Seeking Alpha · 15h ago
Sanofi To Pay $100M To Settle Zantac Cancer Lawsuits
Benzinga · 17h ago
Weekly Report: what happened at SNY last week (0415-0419)?
Weekly Report · 22h ago
More
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

Webull offers Sanofi SA (ADR) stock information, including NASDAQ: SNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNY stock methods without spending real money on the virtual paper trading platform.